Market News AIOpen the app

$100M funding agreement secured by Royalty Pharma with Zealand Pharma for blood disorder treatment.

MarketRead the original at benzinga.com
Neutral

Secured a $100 million funding agreement to enhance its portfolio and revenue from Zealand Pharma's drug.

RPRX · Royalty Pharma plc

AI read · Neutral

The AI's read

Royalty Pharma paid Zealand $100 million for economic rights to rusfertide, including a 1% royalty and milestone payments. Takeda will commercialize and the FDA PDUFA date is Q3 2026, so the asset is real but distant. The deal is tiny versus RPRX's ~$34B market cap, and the stock barely budged (−0.8%) after the news. RSI is neutral, so there’s no clear momentum confirming a big re-rating. Bottom line: fresh news, not a game-changer. We lean neutral because royalties are small and the clinical/regulatory outcome is binary and delayed.

ZLDPF · Zealand Pharma A/S

AI read · Good for ZLDPF

The connection

Received $100 million in funding, which will support the development of its drug rusfertide.

Get alerts for RPRX

Follow Royalty Pharma plc (RPRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RPRX
Free on the App Store and Google Play, or on the web.